SciELO - Scientific Electronic Library Online

 
vol.37 issue3Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic Primary Immune Thrombocytopenia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

EDO SOLSONA, M.ª D. et al. Effectiveness and adequacy of tolvaptan prescription in hospitalized patients. Farm Hosp. [online]. 2013, vol.37, n.3, pp.178-181. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.3.537.

Purpose: To analyse the effectiveness of the use of Tolvaptan and the adequacy of Tolvaptan prescription at a tertiary level hospital. Methods: Prospective observational study of Tolvaptan prescription from October of 2010 to December of 2011. Results: 30 patients (60.0% males) were included, 50.0% of which were diagnosed with heart failure and 30.0% with SIADH. Tolvaptan allowed achieving sodium levels higher than 135 mEq/L in 53.3% of the patients with a mean baseline value of 125.3±7.3 mEq/L. The median treatment duration was 5.0 days (interquartile range = 3-45). A significant increase of uric acid associated to Tolvaptan treatment was observed. The prescription was in agreement to what has been established in GFT in 63.3% of the cases. Conclusions: Tolvaptan increases sodium levels by 7.5 mEq/L, both in SIADH-associated hyponatremia and in heart failure, with an appropriate safety profile.

Keywords : Tolvaptan; Hyponatremia; Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH); Heart failure.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License